CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease
-
April 13, 2026
-
2 min
April 13, 2026
Approximately 3% to 4% of the population over the age of 50 is diagnosed with monoclonal gammopathy of undetermined significance (MGUS). It carries a lifelong risk of progression to multiple myeloma and lymphoma, requiring risk-adapted monitoring by multidisciplinary teams.
by Kimberly Noonan, Kevin Brigle, Charise Gleason, Carrie Bellerive, Mary Steinbach, Deborah Doss
March 4, 2026